NASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price & News $7.77 -0.11 (-1.40%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$7.65▼$7.9850-Day Range$7.77▼$12.2752-Week Range$4.07▼$12.43Volume2.33 million shsAverage Volume1.83 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$13.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aurinia Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside71.6% Upside$13.33 Price TargetShort InterestBearish11.86% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector886th out of 972 stocksPharmaceutical Preparations Industry414th out of 449 stocks 3.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, Aurinia Pharmaceuticals has a forecasted upside of 71.6% from its current price of $7.77.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.86% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 21.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 2.0 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 39.64% of the stock of Aurinia Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.58) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -15.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -15.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aurinia Pharmaceuticals (NASDAQ:AUPH) StockAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.Read More AUPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AUPH Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comIs it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?September 27, 2023 | seekingalpha.comAurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade)October 1, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! September 24, 2023 | americanbankingnews.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Reaffirmed by HC WainwrightSeptember 21, 2023 | finance.yahoo.comAurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT CapitalSeptember 18, 2023 | msn.comWhy Aurinia Pharmaceuticals Stock Is Slumping TodaySeptember 18, 2023 | finance.yahoo.com5 Stocks to Buy as Drug Industry Displays Strong FundamentalsSeptember 11, 2023 | finance.yahoo.comHere's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn SituationOctober 1, 2023 | Goldco (Ad)Biden's Digital Dollar NightmareOn July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late! September 6, 2023 | finance.yahoo.comWall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a BetAugust 21, 2023 | finance.yahoo.comAurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic PipelinesAugust 8, 2023 | msn.comHC Wainwright & Co. Maintains Aurinia Pharmaceuticals (AUPH) Buy RecommendationAugust 5, 2023 | markets.businessinsider.comAurinia Pharmaceuticals (AUPH) Gets a Buy from RBC CapitalAugust 3, 2023 | msn.comAurinia spikes on Q2 earnings beat, guidance raiseAugust 3, 2023 | finance.yahoo.comAurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational ResultsJuly 27, 2023 | finance.yahoo.comInstitutions own 42% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares but individual investors control 56% of the companyJuly 25, 2023 | finance.yahoo.comNasdaq EM Asia Utilities LargeJuly 20, 2023 | finance.yahoo.comAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023July 19, 2023 | finance.yahoo.comLong Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse EventsJuly 18, 2023 | seekingalpha.comAurinia: Strategic Alternatives Could Go Either Way For StakeholdersJuly 11, 2023 | finance.yahoo.comAurinia Pharmaceuticals Stock Shows Rising Relative StrengthJuly 6, 2023 | msn.comCantor Fitzgerald Reiterates Aurinia Pharmaceuticals (AUPH) Overweight RecommendationJuly 3, 2023 | finance.yahoo.comAurinia (AUPH) Up on Paving the Way for a Potential BuyoutJuly 3, 2023 | finance.yahoo.comAurinia (AUPH) Moves 5.7% Higher: Will This Strength Last?June 30, 2023 | msn.comAurinia Pharma could see high $20s to low $30s a share in takeover - analystJune 30, 2023 | msn.comWhy Aurinia Pharmaceuticals Stock Is Marching Higher FridayJune 30, 2023 | marketwatch.comAurinia Pharma Shares Rise 9% As Company Explores Strategic AlternativesSee More Headlines Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Company Calendar Last Earnings8/03/2023Today10/01/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.33 High Stock Price Forecast$15.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+71.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,180,000.00 Net Margins-45.42% Pretax Margin-44.42% Return on Equity-18.05% Return on Assets-14.85% Debt Debt-to-Equity Ratio0.20 Current Ratio6.75 Quick Ratio6.21 Sales & Book Value Annual Sales$134.03 million Price / Sales8.31 Cash FlowN/A Price / Cash FlowN/A Book Value$2.85 per share Price / Book2.73Miscellaneous Outstanding Shares143,420,000Free Float137,255,000Market Cap$1.11 billion OptionableOptionable Beta1.24 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 53)Pres, CEO & Director Comp: $1.34MMr. Joseph M. Miller CPA (Age 49)Chief Financial Officer Comp: $791.92kMr. Matthew Maxwell Donley M.B.A. (Age 54)Exec. VP of Operations & Strategy Comp: $811.82kMr. Stephen P. Robertson (Age 41)Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer Comp: $739.68kDr. Volker Knappertz D.Sc. (Age 58)M.D., Exec. VP of R&D Comp: $742.85kMr. James Archie Harrell Jr. (Age 53)Head of Investor Relations Mr. Fran LynchVP of SalesMr. Michael R. Martin (Age 51)Chief Bus. Officer Ms. Sue EvansSr. VP of Global Regulatory AffairsMr. Scott Habig (Age 63)Chief Commercial Officer More ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAMirum PharmaceuticalsNASDAQ:MIRM89bioNASDAQ:ETNBANI PharmaceuticalsNASDAQ:ANIPViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 38,500 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 67,300 shares on 8/22/2023Ownership: 0.047%California State Teachers Retirement SystemBought 1,933 shares on 8/21/2023Ownership: 0.110%Sunbelt Securities Inc.Bought 74,250 shares on 8/16/2023Ownership: 0.054%Walleye Trading LLCSold 800 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AUPH Stock - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price forecast for 2023? 4 brokers have issued 1-year price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $12.00 to $15.00. On average, they expect the company's share price to reach $13.33 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2023? Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH shares have increased by 79.9% and is now trading at $7.77. View the best growth stocks for 2023 here. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 17,010,000 shares, an increase of 21.8% from the August 31st total of 13,960,000 shares. Based on an average daily volume of 2,180,000 shares, the short-interest ratio is presently 7.8 days. View Aurinia Pharmaceuticals' Short Interest. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, August, 3rd. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.12. The biotechnology company had revenue of $41.49 million for the quarter, compared to analyst estimates of $37.90 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 18.05% and a negative net margin of 45.42%. The business's revenue was up 47.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.25) earnings per share. What ETFs hold Aurinia Pharmaceuticals' stock? ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO). What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings? Aurinia Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $150.00 million-$160.00 million, compared to the consensus revenue estimate of $154.35 million. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $7.77. How much money does Aurinia Pharmaceuticals make? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.11 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. How many employees does Aurinia Pharmaceuticals have? The company employs 300 workers across the globe. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498. This page (NASDAQ:AUPH) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.